8-K: HSPT Corrects Proxy Details for SL Bio Merger Vote

Horizon Space Acquisition II Corp. filed an 8-K to correct trust and transfer agent details and clarify redemption procedures for its upcoming merger vote with SL BIO Ltd.

Summary

• Horizon Space Acquisition II Corp. (HSPT) filed a Current Report on Form 8-K to correct and replace certain references in its Definitive Proxy Statement, filed on January 13, 2026.
• The corrections primarily relate to the trust agent, proxy solicitor, and transfer agent contact information for the proposed business combination with SL BIO Ltd.
• The trust account is maintained by Wilmington Trust, National Association, acting as trustee.
• Shareholders with questions about the proposals or needing additional proxy materials should contact Advantage Proxy, Inc. (Attn: Karen Smith, Toll Free: (877) 870-8565, Collect: (206) 870-8565, Email: ksmith@advantageproxy.com).
• The deadline to request materials from the proxy solicitor is January 27, 2026.
• Shareholders intending to seek redemption of their shares must deliver their Ordinary Shares to the transfer agent, VStock Transfer, LLC (18 Lafayette Place, Woodmere, New York 11598, Attn: Action Team, Email: action@vstocktransfer.com), two business days prior to the scheduled vote.
• The deadline to make a Redemption Election is 5:00 pm Eastern Time on January 30, 2026.
• The Extraordinary General Meeting of HSPT's shareholders is scheduled for February 3, 2026, to vote on the proposed business combination.
• The physical location of the Extraordinary Meeting remains at the offices of Robinson & Cole LLP at 666 Third Avenue, 20th Floor, New York, NY 10017, and virtually via teleconference (+1 813-308-9980, Access Code: 173547).

Sentiment

Score: 5

Explanation: The filing is administrative in nature, providing corrections and clarifications to a previously issued proxy statement. It does not introduce new material financial or strategic information that would significantly alter the company's outlook, maintaining a neutral sentiment.

Positives

• The filing provides clear and specific contact information for the trust agent, proxy solicitor, and transfer agent, enhancing transparency for shareholders.
• Detailed instructions for the redemption process are provided, including deadlines and methods for tendering shares, which helps shareholders understand their rights and obligations.

Negatives

• Significant redemptions could lead to a less liquid trading market for the combined company's shares.
• In the event of significant redemptions, the combined company (PubCo) may not be able to meet Nasdaq listing standards, which is a condition for the business combination.

Risks

• The combined company (SL Bio or PubCo) has a limited operating history.
• The ability of SL Bio or PubCo to identify and integrate acquisitions is uncertain.
• General economic and market conditions could impact demand for the combined company's products.
• There is a risk of inability to complete the proposed Business Combination.
• The anticipated benefits of the proposed Business Combination may not be recognized, potentially affected by the amount of cash available after shareholder redemptions.
• The combined company may be unable to meet stock exchange listing standards following the consummation of the proposed Business Combination.
• Costs related to the proposed Business Combination could be higher than expected.
• The proposed Business Combination may not close due to failure to receive required security holder approvals or other closing conditions.

Future Outlook

Forward-looking statements indicate expectations regarding the advantages and growth of the combined company, its cash position post-closing, and the ability of HSPT and SL Bio to consummate the proposed Business Combination and its timing. These statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Management Comments

• The report was signed on behalf of Horizon Space Acquisition II Corp. by Mingyu (Michael) Li, Chief Executive Officer.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) nearing the completion of its de-SPAC transaction, or business combination. The administrative corrections and detailed redemption procedures are common as SPACs finalize the merger process and prepare for shareholder votes, reflecting the complex regulatory and logistical requirements of such transactions.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Directly impacted by the clarified redemption process and deadlines, as well as the potential for a less liquid trading market and inability to meet Nasdaq listing standards if significant redemptions occur.
• Investment Professionals: Provided with updated and corrected information essential for advising clients on the upcoming merger vote and redemption decisions.

Next Steps

• Shareholders to request additional proxy materials by January 27, 2026.
• Shareholders to make redemption elections by January 30, 2026.
• Extraordinary General Meeting of shareholders to be held on February 3, 2026, to vote on the Business Combination Proposals.
• Consummation of the Business Combination between HSPT and SL BIO Ltd., subject to shareholder approval and other conditions.

Key Dates

Recommendation

The filing provides administrative corrections and clarifications regarding the business combination process, particularly redemption procedures. It does not introduce new material financial or strategic information that would alter the fundamental investment thesis for or against the merger. The risks associated with redemptions are inherent to SPAC transactions and were previously disclosed. Therefore, a 'hold' recommendation is appropriate as no new information warrants a change in investment position based solely on this filing.

Keywords

SPAC, Business Combination, Merger, Proxy Statement, Redemption Rights, SL BIO Ltd., Horizon Space Acquisition II Corp., Nasdaq Listing, Trust Account